Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics Stock Forecast

Stock Price Forecast

According to 6 professional analysts, the 12-month price target for Arcutis Biotherapeutics stock ranges from a low of $15 to a high of $22. The average analyst price target of $19 forecasts a 21.56% increase in the stock price over the next year.

Price Target: $19.00 (+21.56%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$15	$19	$19	$22
Change	-4.03%	+21.56%	+21.56%	+40.75%

Analyst Ratings

The average analyst rating for Arcutis Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	4	4	4	4	4	4
Buy	1	1	1	1	1	1
Hold	1	1	1	1	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	7	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Serge Belanger Needham	Needham	Strong Buy Maintains $20 → $22	Strong Buy	Maintains	$20 → $22	+40.75%	Aug 7, 2025
Richard Law Goldman Sachs	Goldman Sachs	Hold Initiates $18	Hold	Initiates	$18	+15.16%	Jul 25, 2025
Serge Belanger Needham	Needham	Strong Buy Reiterates $20	Strong Buy	Reiterates	$20	+27.96%	May 23, 2025
Serge Belanger Needham	Needham	Strong Buy Reiterates $20	Strong Buy	Reiterates	$20	+27.96%	Apr 9, 2025
Seamus Fernandez Guggenheim	Guggenheim	Strong Buy Reiterates n/a	Strong Buy	Reiterates	n/a	n/a	Apr 3, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

318.06M

Increased by 61.83%

from 196.54M

Revenue Next Year

434.32M

Increased by 36.55%

from 318.06M

EPS This Year

-0.57

from -1.16

EPS Next Year

0.16

from -0.57

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	3.69M	59.61M	196.54M	318.06M	434.32M	580.85M
Revenue Growth	-	-	-	1,517.09%	229.74%	61.83%	36.55%	33.74%
EPS	-3.80	-4.18	-5.66	-3.78	-1.16	-0.57	0.16	1.20
EPS Growth	-	-	-	-	-	-	-	651.83%
Forward PE	-	-	-	-	-	-	97.87	13.02
No. Analysts	-	-	-	-	-	9	9	9

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	343.4M	476.7M	764.5M
Avg	318.1M	434.3M	580.9M
Low	286.2M	392.0M	443.5M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	74.7%	49.9%	76.0%
Avg	61.8%	36.6%	33.7%
Low	45.6%	23.2%	2.1%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-0.37	0.42	2.82
Avg	-0.57	0.16	1.20
Low	-0.72	-0.29	0.30

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	1,668.6%
Avg	-	-	651.8%
Low	-	-	90.2%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.